With this in mind, we aimed to (1) evaluate the basal levels of Bcl-2 and Beclin-1 in HeLa and CaSki cell lines, (2) silence Bcl-2 as a means of defining its role during cisplatin treatment, and finally analyse pre-malignant low-grade squamous intraepithelial lesions (LSILs), high-grade squamous intraepithelial lesions (HSILs), as well as malignant cervical tissue for the presence of Bcl-2 under basal conditions in order to evaluate its possible role in vivo during the progression of cervical cancer and validate the in vitro results. This evidence concerns the gene BCL2 and cervical cancer.